The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

“Start low, go slow.” Geriatric pharmacology texts and recent systematic reviews (e.g., on dosing of oncology drugs) warn ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. A Passion for Issues that Matter to Americans 50-Plus is All You ...

The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

Common iron supplement side effects include gastrointestinal problems, decreased zinc absorption and interaction with certain ...